On October 23, 2025, GSK plc announced that the FDA approved Blenrep for treating adult patients with relapsed/refractory multiple myeloma, showing a 51% reduced risk of death compared to previous treatments. This significant approval addresses a critical need for effective therapies in a patient population with limited options.